Literature DB >> 8667646

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes.

J Lotem1, L Sachs.   

Abstract

Hematopoietic cells require certain cytokines including colony-stimulating factors and interleukins to maintain viability. Without these cytokines the program of apoptotic cell death is activated. Cells from many myeloid leukemias require cytokines for viability, and apoptosis is also activated in these leukemic cells after cytokine withdrawal resulting in reduced leukemogenicity. The same cytokines protect normal and leukemic cells from induction of apoptosis by irradiation and cytotoxic chemotherapeutic compounds. This suggests that decreasing the levels of viability inducing cytokines may increase the effectiveness of cytotoxic anti-cancer therapy. The susceptibility of normal and cancer cells to induction of apoptosis is also regulated by the balance between apoptosis-inducing genes such as the tumor suppressor wild-type p53, and c-myc and bax, and apoptosis-suppressing genes such as the oncogene mutant p53, and bcl-2 and bcl-XL. Cell susceptibility to induction of apoptosis in leukemic cells could be enhanced by increased expression of apoptosis-inducing genes and/or decreased expression of apoptosis-suppressing genes. Modulation of expression of apoptosis-regulating genes should thus also be useful for improvement of anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667646

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin.

Authors:  J Lotem; R Kama; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents.

Authors:  J Lotem; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 3.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

4.  Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines.

Authors:  J Lotem; M Peled-Kamar; Y Groner; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

5.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

6.  Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Authors:  Steven M Kornblau; David McCue; Neera Singh; Wenjing Chen; Zeev Estrov; Kevin R Coombes
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

7.  Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.

Authors:  N N Ahmed; H L Grimes; A Bellacosa; T O Chan; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 8.  Differentiation, apoptosis, and function of human immature and mature myeloid cells: intracellular signaling mechanism.

Authors:  Akira Yuo
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

9.  Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds.

Authors:  J Lotem; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

10.  Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis.

Authors:  Sylvia Mansilla; Benjamin Piña; José Portugal
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.